Logo

Johnson & Johnson Gains the CHMP’s Positive Opinion for Rybrevant (Amivantamab) as a 1L Treatment of NSCLC

Share this
Johnson & Johnson

Johnson & Johnson Gains the CHMP’s Positive Opinion for Rybrevant (Amivantamab) as a 1L Treatment of NSCLC

Shots: 

  • The company's Rybrevant + CT (carboplatin & pemetrexed) has gained the CHMP’s positive opinion as a 1L therapy for NSCLC associated with activating EGFR exon 20 insertion mutations  

  • The opinion was based on the P-III (PAPILLON) trial assessing the safety & efficacy of Rybrevant + CT vs CT in NSCLC patients (n=308) with EGFR exon 20 insertion mutations that showed improved PFS (1EP) & a trend favoring interim OS. 7% TRAEs leading to discontinuation 

  • Rybrevant is a bispecific Ab targeting activated & resistant EGFR mutation as well as MET mutations and amplifications 

Ref: Johnson & Johnson  | Image: Johnson & Johnson 

Related Post:- Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Combined with Chemotherapy as a 1L Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions